Alternative za pretraživanje:
"dao open" » "ao open" (Proširi pretraživanje), "caso open" (Proširi pretraživanje), "two open" (Proširi pretraživanje), "daao open" (Proširi pretraživanje), "dao opens" (Proširi pretraživanje), "da1 open" (Proširi pretraživanje)
"so open" » "ao open" (Proširi pretraživanje), "caso open" (Proširi pretraživanje), "two open" (Proširi pretraživanje), "sao open" (Proširi pretraživanje), "so opens" (Proširi pretraživanje), "s1 open" (Proširi pretraživanje)
"do open" » "two open" (Proširi pretraživanje), "oto open" (Proširi pretraživanje), "dao open" (Proširi pretraživanje), "do opens" (Proširi pretraživanje), "d1 open" (Proširi pretraživanje)
"esmo open" » "esmao open" (Proširi pretraživanje), "esmo opens" (Proširi pretraživanje), "esm1 open" (Proširi pretraživanje)
"o open" » "ao open" (Proširi pretraživanje), "o opens" (Proširi pretraživanje), "1 open" (Proširi pretraživanje)
Prikaz rezultata 1 – 20 od 1.029 za pretraživanje '(("esmo open") OR ((((("so open") OR ("do open"))) OR ((("o open") OR ("dao open"))))))', vrijeme pretraživanja: 1,68s Detaljiziraj rezultate
AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open
ESMO Open—Cancer Horizons and the future of oncology

CSCO joins ESMO Open—Cancer Horizons
ESMO Open: news in breast cancer 2019

ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)
ESMO Open special series on new emerging targets in cancer immunotherapy

Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment
One year of ESMO Open: Cancer Horizons—where are we going from here?

Plasmodesmata. A Not So Open-and-Shut Case
Introducing a new ESMO Open article series: how I treat side effects of immunotherapy

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion
Desafios do Open Design

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]

Adoção do Open Peer Review
How do Openers Contribute to Student Learning?

Criptografia digital: implementação do OpenPGP
Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]

Alati za pretraživanje: Preuzmi RSS sažetak — Pošalji ovo pretraživanje e-poštom — Spremi pretraživanje